Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 14, 2020

NIH launches clinical trial for Covid-19 therapies

The US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) has launched the ACTIV-5 Big Effect Trial (ACTIV-5/BET) to test Boehringer Ingelheim and AbbVie’s Risankizumab in conjunction with the antiviral drug remdesivir, compared to a placebo plus remdesivir.

The US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) has launched the ACTIV-5 Big Effect Trial (ACTIV-5/BET) to test Boehringer Ingelheim and AbbVie’s Risankizumab in conjunction with the antiviral drug remdesivir, compared to a placebo plus remdesivir.

It will also analyse Humanigen’s investigational monoclonal antibody lenzilumab plus remdesivir as a treatment in patients hospitalised with Covid-19.

ACTIV-5/BET is designed to assess whether approved therapies or investigational drug candidates can be used against Covid-19 and thereby progress into larger clinical trials if proven successful.

The Phase II adaptive, randomised, double-blind, placebo-controlled trial will compare different investigational therapies to a common control arm to analyse the effects of these treatments.

Each arm will enrol about 100 hospitalised patients in 40 US sites and each study site will test a maximum of three treatments at once.

Last year, risankizumab was approved in the US as a treatment for severe plaque psoriasis.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Lenzilumab is currently in a Phase III Covid-19 study and a Phase Ib/II study as sequenced therapy with CAR-T treatments.

Participants assigned to receive risankizumab will be given a single intravenous dose on the first day of the trial.

Those assigned to receive lenzilumab will be administered a 600mg intravenous infusion every eight hours for a total of three times.

The main objective of the trial is to analyse the clinical efficacy of the different investigational treatments in hospitalised adults on day eight.

Time to recovery will become the trial’s secondary point of evaluation.

NIH director Francis Collins said: “The ACTIV-5/BET study aims to streamline the pathway to finding urgently needed Covid-19 treatments by repurposing either licensed or late-stage-development medicines and testing them in a way that identifies the most promising agents for larger clinical studies in the most expedient way possible.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU